Company Overview and News
Armo BioSciences (NASDAQ:ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (NYSE:LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO at a $500 million valuation. Lilly offered to pay $50 per share for Armo, a three-fold increase from the IPO price and a 67% jump from its previous close, to acquire the company with its portfolio of immuno-oncology candidates.
WeDoctor Holdings, an online health care services provider backed by Tencent Holdings, has completed a US$500 million private share sale, in the second major equity financing deal in China’s nascent “health-tech” sector in three weeks.
A monitoring system designed to collect biometric data on outpatients suffering from chronic diseases will be trialled in mainland hospitals this year, a programme that British software developer Medopad and its Chinese partners regard as an important step in developing new services in the “health tech” business.
ATTO led Industrials with an estimated net gain of 84.92% calculated 3/29/18, by 7 analysts, while NWSGY was top stock by yield at 16.08%.
80 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 3/26/18. Yields above 12.2% narrowed the list to 30 for comparison.
Buying of shares in their own companies by Hong Kong directors rebounded sharply in the March 19 to March 23 week, according to filings to the stock exchange, while selling rose for a third straight week.
79 U.S. stocks displayed 10%+ forward yield, $5+ prices, and $100M+ market caps as of 2/26/18. Yields above 12.2% narrowed the list to 30 for comparison.
TNP led Industrials with an estimated net gain of 55.43% calculated 2/23/18, by 13 analysts, while NAP was top stock by yield at 18.74%.
British health tech start-up Medopad has raised $28 million in its first round of financing, after having struck $100 million worth of deals in China with firms including Tencent.
DLNG led the industrials with an estimated net gain of 29.58% calculated 1/23/18, by 9 analysts, while NAP was top stock by yield at 17.79%.
Hong Kong is aiming for an 18 per cent share of an industry that can create 15,340 jobs, add HK$10 billion in tax receipts and contribute HK$430 billion to the city’s economy.
A 500 square foot flat in a normal high-rise building requires 150 tonnes of conventional concrete. With super-strong lightweight concrete, the building foundations will be 20pc cheaper, claims one firm
Integrating Innovation, Art and Commerce, New K11 Atelier office concept redefines work space at game-changing Victoria Dockside site in Kowloon; New mixed-use commercial building makes waves in drawing global finance firms Mizuho Bank and Taipei Fubon Bank across the Harbour to the iconic Tsim Sha Tsui harbourfront
Game-changing, mixed-use harbourfront development spearheaded by New World Development aims to set new standards in art, design and leisure
Air China is the only national flag carrier of China and a member of Star Alliance, the world's largest airline alliance. It is also the only Chinese civil aviation enterprise listed in "The World's 500 Most Influential Brands".
8h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
8h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
18h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...